Related Experiment Videos
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
Anders Waage1, Peter Gimsing, Gunnar Juliusson
1Department of Haematology, University Hospital Trondheim, N-7006 Trondheim, Norway. anders.waage@medisin.ntnu.no
British Journal of Haematology
|April 3, 2004
Summary
Thalidomide treatment showed modest efficacy in refractory multiple myeloma patients, with 20% achieving some response and a median survival of 12 months. Early M protein reduction was observed, with hemoglobin improving over time.
Area of Science:
- Hematology
- Clinical Pharmacology
Background:
- Multiple myeloma is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
- Patients refractory to standard chemotherapy often have limited treatment options.
Purpose of the Study:
- To evaluate the efficacy and pharmacokinetics of thalidomide in patients with refractory or relapsed multiple myeloma.
- To assess response based on M-protein reduction, hemoglobin levels, renal function, and pain.
Main Methods:
- Sixty-five patients with refractory/relapsed multiple myeloma received thalidomide (200-800 mg/d).
- Response evaluation included M-protein reduction, hemoglobin, renal function, and pain.
- Pharmacokinetic analysis of thalidomide blood concentrations was performed in 40 patients.
Main Results:
- Overall response rate was 34% (14% minor, 14% partial, 6% complete).
- Median survival was 12 months, with 29% alive at follow-up.
- Early M-protein reduction was observed within 3-5 weeks; hemoglobin increased significantly after 3 months.
Conclusions:
- Thalidomide demonstrates modest efficacy in heavily pretreated multiple myeloma patients.
- The drug can induce early M-protein reduction and delayed hemoglobin improvement.
- No correlation was found between thalidomide concentration and clinical effect after 12 weeks.